3320.HK
3320.HK
HK0000311099
CHINARES PHARMA
Loading chart...

Company Profile

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular, metabolism, intravenous infusion, and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operating retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, Kun Zhong Yao, and Tasly to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited operates as a subsidiary of CRH (Pharmaceutical) Limited.

Related stocks

RGC
RGC • Hong Kong SAR China
Regencell Bioscience Holdings L
7.35 USD
3.64B USD 1Y -60.7%
002262.SZ
002262.SZ • China
NHWA
21.74 CNY
3.3B USD 1Y -21.8%
6887.HK
6887.HK • China
SUNSHINE PHARMA
40.06 HKD
2.93B USD 1Y -16.6%
002773.SZ
002773.SZ • China
KHPG
20.66 CNY
2.85B USD 1Y -43.6%
HCM
HCM • Hong Kong SAR China
HUTCHMED (China) Limited
14.1 USD
2.45B USD 1Y -16.6%
EMCURE.NS
EMCURE.NS • India
EMCURE PHARMACEUTICALS L
1,833.5 INR
3.59B USD 1Y +31.4%
HCM.L
HCM.L • Hong Kong SAR China
HUTCHMED (CHINA) LIMITED ORD US
203 GBp
2.33B USD 1Y -11.8%
4540.T
4540.T • Japan
TSUMURA & CO
3,772 JPY
1.78B USD 1Y +5%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
38.0% p.a.
Max Drawdown (5Y)
-46.8%
Sharpe Ratio (5Y)
0.00
Beta Factor
-0.42
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (38.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -75.0% in the extended horizon.
ende